For accurate detection of all types of genetic aberrations, various technologies are required. By combining information from multiple technologies, researchers can analyse complex samples and get the most complete overview of disease-driving mutations.
OGT offers an integrated portfolio of products providing clinical researchers with the most advanced tools available to study hematological disorders, including CytoCell® fluorescence in-situ hybridization (FISH) probes and myProbes® custom FISH probes, SureSeq™ next generation sequencing (NGS) panels and myPanel™ custom panels, and CytoSure® array products and custom arrays.
Our products are backed by deep technical expertise and dedicated customer support.
The EVI1 (MECOM) Breakapart FISH Probe Kit consists of a 158kb probe, labeled in Texas Red, telomeric to the D3S4415 marker and including the LRRC34 gene, a FITC green probe covering a 181kb region, including the entire EVI1 (MECOM) gene and flanking regions and a PF-415 blue probe, which covers a 563kb region centromeric to the EVI1 (MECOM) gene, including the D3S1614 marker.
View ProductThe P53 (TP53) Deletion FISH Probe Kit consists of a 161kb probe, labeled in Texas Red, covering the whole P53 (TP53) gene, extending 74kb telomeric to the gene and covering a region centromeric to the gene, to just beyond the marker D17S655; and a probe, labelled in FITC green, covering the chromosome 17 centromere (D17Z1) region.
View ProductThe SureSeq Pan-Myeloid Panel accurately detects SNVs and indels in genes such as CEBPA, JAK2, CALR and MPL, as well as structural variants including FLT3-ITDs and KMT2A-PTDs, providing researchers with a single NGS workflow delivering a comprehensive picture of the genetic make-up of each myeloid sample. The figure (above) shows FLT3-ITDs of various sizes and even regions containing multiple ITDs can be confidently detected. ITD sizes are [A] 174 bp, [B] 225 bp, [C] 195 bp with additional 6 bp, [D] 120 bp and [E] 168 bp with additional 69 bp.
View ProductThe SureSeq CLL + CNV Panel has been designed in collaboration with recognized cancer experts to detect 13 key genes and 5 chromosomal regions implicated in CLL progression. The figure (above) compares SureSeq CLL + CNV Panel data with array data for a 42.7Mb deletion of 11q covering ATM (top) and a 0.6Mb biallelic loss called within a larger ~1Mb single allele deletion in the region covering DLEU2/DLEU1/DLEU7 on chromosome 13q (bottom).
View Product
